Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Aussie of the Year announces new vaccine trial


The technology used in the world’s first cervical cancer vaccine will be tweaked to fight the most common sexually transmitted disease, genital warts.

Australian of the Year and University of Queensland (UQ) cervical cancer vaccine creator Professor Ian Frazer launched a therapeutic vaccine trial for genital warts today (Tuesday, February 7).

Patients from Brisbane and China will take part in the joint project for UQ’s cancer research centre, the Centre for Immunology and Cancer Research (CICR) and the hospital’s sexual health service, Princess Alexandra Sexual Health (PASH).

Professor Frazer said the vaccine used virus-like particles to deliver an antigen (protein that produces immunity) for genital warts similar to the cervical cancer vaccine.

"It will target the main causes of visible genital warts which are human papillomavirus (HPV6) and (HPV11)," Dr Frazer said.

A pilot study of vaccine CICRVAX6 by UQ’s Chinese research partner, Wenzhou Medical College, showed the vaccine was potentially effective at treating genital warts in humans.

Now PASH is running a larger trial and needs 120 men and 120 women who have recurring genital warts.

Participants must be aged between 18 and 65 years, should not be pregnant or immunosuppressed and will be required for seven medical visits, with their travel costs refunded.

Trial Manager and PASH Senior Medical Officer Dr David Jardine said patients would receive standard treatment for genital warts and two vaccine shots, which are saline solutions injected in the upper arm, over two months.

"The incentives for people are that they get free consultations, free treatment, free vaccines and their travelling expenses paid," Dr Jardine said.

He said conventional wart treatments of freezing, burning or painting visible warts with acid might not switch off the active infection.

The 18-month trial will be launched in conjunction with Wartfest, an annual expo about new developments and treatments for warts, HPV and cancer, featuring expert speakers from Australia and Canada.

Genital warts are transmitted by skin contact and the 2003 Australian Study of Sex and Relationships of 20,000 adults revealed four percent of people had had visible genital warts.

Professor Frazer said developing a preventative warts vaccine or a combined vaccine for cervical cancer and genital warts was one of the next steps if the therapeutic trial was successful.

Miguel Holland | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>